Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals Inc (NQ: DCPH )

25.59 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Deciphera Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
Via Benzinga
Earnings Preview: Deciphera Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings for Deciphera Pharmaceuticals
Via Benzinga
Recap: Deciphera Pharmaceuticals Q1 Earnings
Via Benzinga
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals' Investigational Drug Shows Encouraging Response Rates In Rare Type Of Cancer
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT)  
Via Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing. 
Via InvestorPlace
3 Under-the-Radar Biotech Stocks to Buy in 2023
All three biotech companies focus on oncology therapies. 
Via The Motley Fool
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Why Shares of Deciphera Pharmaceuticals Rose This Week
The company's shares rose after the company reported second-quarter earnings. 
Via The Motley Fool
Deciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: Analyst
Stifel upgraded Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) to Buy from Hold, with a price target of $20 from $14, after reevaluating the competitive landscape for the 2L GIST market. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on... 
Via Benzinga
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.